Cellogen Therapeutics
New Delhi cell and gene therapy company founded in 2021 developing indigenous bispecific CAR-T therapies for blood cancers; its dual-antigen CD19/CD20 CAR-T is the lead program, with earlier-stage work in beta-thalassemia and sickle-cell disease and GMP manufacturing in Noida.
Headquarters
New Delhi, India
Year Founded
2021
Founders
Gaurav Kharya, Tanveer Ahmad
Country
India
Financial Information
Funding Stage
Venture round
Recent Funding
$2.4M (INR 200M)
Funding By
Kotak Life Sciences Fund I (Kotak Alternate Asset Managers); previously NATCO Pharma
Core Technology
Bispecific CAR-T engineering with dual-antigen targeting and in-house GMP manufacturing
Product Type
Cell Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: N/A
- Clinical Trial Registration: Phase I planned with CMC Vellore (India)
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
NATCO Pharma (earlier backer)
Academic / Hospital Tie-ups
CMC Vellore (planned Phase I)
CRO/CDMO Partnerships
In-house GMP manufacturing facility in Noida
Market & Differentiation
Indigenous bispecific CAR-T aimed at lowering the cost of blood-cancer cell therapy in India